Compare RCAT & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCAT | CERT |
|---|---|---|
| Founded | 2002 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Retail: Computer Software & Peripheral Equipment |
| Sector | Industrials | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2017 | 2020 |
| Metric | RCAT | CERT |
|---|---|---|
| Price | $10.32 | $8.01 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $20.00 | $11.67 |
| AVG Volume (30 Days) | ★ 8.4M | 3.8M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.50 |
| EPS | N/A | ★ N/A |
| Revenue | $17,836,382.00 | ★ $418,838,000.00 |
| Revenue This Year | $271.60 | $4.18 |
| Revenue Next Year | $41.21 | $5.39 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 79.95 | 8.75 |
| 52 Week Low | $5.77 | $4.45 |
| 52 Week High | $18.78 | $13.88 |
| Indicator | RCAT | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 61.78 | 62.55 |
| Support Level | $7.16 | $6.15 |
| Resistance Level | $11.74 | $8.39 |
| Average True Range (ATR) | 0.70 | 0.41 |
| MACD | 0.42 | -0.03 |
| Stochastic Oscillator | 86.19 | 84.05 |
Red Cat Holdings Inc is a drone technology company integrating robotic hardware and software for military, government, and commercial operations. Its suite of solutions includes the Arachnid family of ISR and precision strike drones, which includes the Black Widow, a small unmanned ISR system; and WEB (Warfighter Electronic Bridge) GCS, designed to command and control an entire drone family of systems for military operations. Its other offerings include Edge 130 Blue drone systems, Trichon, a fixed-wing VTOL for extended endurance and range, and FANG FPV drones optimized for military operations with precision strike capabilities. The firm's Division includes Teal, FlightWave, and Blue Ops.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.